Community Access to Antibiotic Treatment for Sexual Pneumonia
Community access to pneumonia (Community-acquired pneumonia, CAP) is defined as infectious pneumonia that occurs outside the hospital, including pneumonia that occurs during the average post-institutional submersion period with a pathogen infection with a defined insulation period. Antibiotic treatment is one of the key components of community access to treatment for sexually transmitted pneumonia.
I. Community access to common pathogens for pneumonia
Communities receive a wide range of pathogens for the disease, mainly bacteria, viruses, secondarys, chlamydia, etc. Of these, the most common bacterial pathogens are pneumococcus, haemophilus influenzae, catamola, etc.; the viral pathogens are mainly influenza viruses, sub-influenza viruses, respiratory combination viruses, etc.; and the atypical pathogens are mainly paragens, chlamydia, legions, etc. The distribution of pathogens may vary from region to region, from population to population, and from season to season.
Basic principles of antibiotics treatment
Early treatment
Antibiotic treatment should be provided as soon as suspected communities have access to sexually transmitted pneumonia in order to increase the cure rate and reduce mortality. In general, it is appropriate to start antibiotic treatment within four hours of the diagnosis.
2. Antibiotic selection for pathogens
An initial diagnosis of the possible pathogens and the choice of antibiotics that are sensitive to them are based on the age of the patient, underlying diseases, clinical performance, laboratory tests, etc. For people with serious illnesses, empirical anti-infection treatment can be provided before the pathogen is identified, and the antibiotics can be adapted to the drug-sensitive results once the pathogen is identified.
3. Reasonable joint use
Joint use of antibiotics to improve antibacterial effectiveness and reduce the production of drug-resistant bacteria may be considered for patients with severe conditions or a combination of pathogens. However, joint use should be based on the principles of sound and effective use and avoid unnecessary association.
4. Footstep therapy
The course of treatment for antibiotics is determined on the basis of the patient ‘ s condition, the type of pathogen, etc., and is generally 7-14 days. In the case of patients with severe illnesses or with specific pathogen infections, the process may need to be extended appropriately.
Empirical antibiotic treatment programme
1. Persons with young and unbasic diseases
The pathogens common to such patients are pneumocococcal, haemophilus influenzae, pneumonia spa etc. Optimals (e.g., Achicillin), penicillin (e.g., Amosilin), first- or second-generation septoxin (e.g., hairfuran).
• For example, AchCycin 0.5g may be given once a day for oral treatment; or Amosilin 1.0g for oral treatment three times a day; or PFC 0.5g for oral treatment twice a day.
2. Older persons or persons with basic illnesses
The pathogens common to such patients are pneumococcus, haemophilus influenzae, aerobic gluccus, yellow grapes, etc. Optimals of the second or third generation can be used (e.g., hair thawing, hair thorium), β-neamide/beta-neamide inhibitors (e.g., Amosilin/Clavic acid), fluorophenone (e.g., left oxyfluorosalt) etc.
• For example, head spores 2.0g per day, with IV drops; or Amosicillin/Clavic acid 1.2g, with IV drops three times per day; or left oxyfluza 0.5g, with IV drops.
3. Severely ill persons requiring hospitalization
The pathogens common to such patients are pneumocococcus, aerobic glycoccus, yellow grapes, legionella, etc. Third-generation hexaphene (e.g., thalamus), β-neamide/beta-neamide inhibitors, carbon methacne (e.g., amphetamine) and fluorophenolone, among others, may be used, and may be combined with large ringed esters or hydrophenone.
• For example, a tungsten of 2.0 g per day may be given twice, with an intravenous drip; or an amphetamine / West stitatin 1.0g per day, with three intravenous drips; combined acceacin 0.5g per day, with an intravenous drip; or a left oxen fluoride 0.5g, with an intravenous drip.
IV. Aligning antibiotic treatment programmes with pathogens
Pneumococcus
For penicillin-sensitive streptococcus, the choice is for penicillin G, amosicillin, etc., and for penicillin-mediated or drug-resistant streptococcus, the choice is for head spines, head gills, flulanone, etc.
For example, if the pathogens are penicillin-sensitive pneumocococcus, penicillin G 2.4 million units can be given four times a day for intravenous dripping; or Amosilin 1.0g for three times a day for intravenous dripping. If the pathogen is penicillin-mediated or drug-resistant pneumocococcus, the head spines can be given 2.0 g per day, with an intravenous drip; or left oxen fluoride 0.5 g with a daily and intravenous drip.
Haemophilus influenzae
• Second- or third-generation septactin, β-neamide/beta-neamide inhibitors, fluoroquinone, etc.
• For example, PFP 0.5g may be given twice a day for oral treatment; or Amosilin/Clavic acid 1.2g may be given three times a day for intravenous dripping; or Left Oxygen 0.5g may be given once a day for intravenous dripping.
Pneumonia terraforms
• Optimals such as large cyclopentone, fluorophenone, etc.
• For example, Achicillin 0.5g may be given once a day for oral or intravenous dripping; or left oxen fluorine 0.5g for daily oral or intravenous dripping.
4. Gluccus gold
• For methoxicillin-sensitive golden fungus, phenolin, chloroxin, etc., and for methoxysilin-resistant gluccus, vancomicin, Linamamine, etc.
• For example, if the pathogens are methoxysilincrin-sensitive golden spherical fungi, benzophthalm 2.0g per day, four times per day, intravenous dripping; or chlorophenolin 2.0g, four times per day, intravenous dripping. If the pathogen is metoxysilin-resistant golden spherical fungi, it can be given Vungucin 1.0 g, twice a day, with an intravenous drip; or Rinetamine 0.6 g, twice a day, with an intravenous drip.
V. Attention to antibiotics
1. Attention to adverse effects of drugs
Different antibiotics can give rise to different adverse reactions, such as allergies, gastrointestinal responses, and liver and kidney function damage. In the course of treatment, changes in the patient ‘ s condition should be closely observed and adverse reactions detected and addressed in a timely manner.
2. Avoiding the misuse of antibiotics
(c) Strictly master the adapted proof of antibiotics and avoid their misuse. There is generally no need for antibiotics to treat HIV-related infections in communities where they occur.
3. Rationally adjusted dosages and sessions
The dose of antibiotics and the course of treatment are reasonably adjusted to the patient ‘ s age, weight, liver and kidney function. Avoid overdose or long treatment to avoid the generation of drug-resistant bacteria and double infections.
4. Strengthening support for treatment
Community access to antibiotics for patients with sexually transmitted pneumonia should be accompanied by increased nutritional support, the correction of hydrolysis disorders, and the maintenance of open respiratory tracts to increase the resilience and resilience of patients.
In short, antibiotics treatment is one of the key means of community access to treatment for sexually transmitted pneumonia. In the course of treatment, reasonable antibiotic treatments should be selected, taking into account the specific circumstances of the patient, and attention should be paid to the adverse effects of the drug, to the avoidance of the abuse of antibiotics, to the rationalization of the dose and course of treatment, and to the enhancement of support for treatment, so as to improve the patient ‘ s healing rate and quality of life.
